VAXNEUVANCE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $80,601 | 561 | 478 |
| 2023 | $244,172 | 1,331 | 1,024 |
| 2022 | $63,812 | 634 | 563 |
| 2021 | $229.52 | 13 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $218,045 | 99 | 56.1% |
| Food and Beverage | $95,501 | 2,158 | 24.6% |
| Travel and Lodging | $61,095 | 218 | 15.7% |
| Unspecified | $13,114 | 2 | 3.4% |
| Education | $1,059 | 62 | 0.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STUDY NAME#Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients | Merck Sharp & Dohme LLC | $6,654 | 0 |
| Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients | Merck Sharp & Dohme LLC | $6,460 | 0 |
Top Doctors Receiving Payments for VAXNEUVANCE — Page 78
Manufacturing Companies
- Merck Sharp & Dohme LLC $388,584
- Merck Sharp & Dohme Corporation $229.52
Product Information
- Type Biological
- Total Payments $388,814
- Total Doctors 1,929
- Transactions 2,539
About VAXNEUVANCE
VAXNEUVANCE is a biological associated with $388,814 in payments to 1,929 healthcare providers, recorded across 2,539 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2021 to 2024. In 2024, $80,601 was paid across 561 transactions to 478 doctors.
The most common payment nature for VAXNEUVANCE is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($218,045, 56.1% of total).
VAXNEUVANCE is associated with 2 research studies, including "STUDY NAME#Response to guideline-concordant pneumococcal vaccination strategy in cardiac transplant candidates and recipients" ($6,654).